Li Jiaqi, Wang Lei, Li Ziqi, Sun Yihan, Yu Meiyu, Xiao Boying, Lv Junyuan, Li He, Wang Jianming, Wen Hao
Department of Clinical Medicine, China Medical University, Shenyang, Liaoning, China.
Department of Vascular Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ann Med Surg (Lond). 2025 May 20;87(7):4414-4425. doi: 10.1097/MS9.0000000000003379. eCollection 2025 Jul.
Hand, foot, and mouth disease (HFMD) is a viral infection, primarily caused by gastrointestinal viruses. Xuebijing (XBJ) injection, widely used in China for treating inflammatory conditions like sepsis, may offer therapeutic benefits for HFMD. This study aimed to evaluate the efficacy and safety of adjunctive XBJ therapy for HFMD.
Databases were systematically searched until February 2024. Meta-analysis used random or fixed-effect models, with outcomes reported as standardized mean differences (SMD) or relative risks (RR) and 95% confidence intervals (CI). Heterogeneity was assessed via Cochran's test and index. Network pharmacology, molecular docking, and molecular dynamics simulations identified active XBJ components and their targets in HFMD.
Six randomized controlled trials (RCTs) involving 786 participants were included. XBJ significantly improved the total effective rate (RR = 1.19, < 0.01), shortened fever duration (SMD = - 1.78, < 0.01), reduced rash resolution time (SMD = - 1.13, < 0.01), and decreased hospital stay (SMD = - 1.20, < 0.01). Pharmacological analysis identified four active XBJ components targeting IFN-γ, TLR4, and TNF-α in HFMD.
XBJ as adjunctive therapy improves outcomes in HFMD and is safe, with specific molecular targets identified for its therapeutic effects.
手足口病（HFMD）是一种病毒感染性疾病，主要由肠道病毒引起。血必净（XBJ）注射液在中国广泛用于治疗脓毒症等炎症性疾病，可能对手足口病具有治疗作用。本研究旨在评估XBJ辅助治疗手足口病的疗效和安全性。
系统检索数据库至2024年2月。荟萃分析采用随机或固定效应模型，结果以标准化均数差（SMD）或相对危险度（RR）及95%置信区间（CI）表示。通过Cochran检验和I²指数评估异质性。网络药理学、分子对接和分子动力学模拟确定了XBJ在手足口病中的活性成分及其靶点。
纳入6项随机对照试验（RCT），共786名参与者。XBJ显著提高了总有效率（RR = 1.19，P < 0.01），缩短了发热持续时间（SMD = -1.78，P < 0.01），缩短了皮疹消退时间（SMD = -1.13，P < 0.01），并缩短了住院时间（SMD = -1.20，P < 0.01）。药理学分析确定了XBJ的四种活性成分，它们在手足口病中靶向干扰素-γ、Toll样受体4（TLR4）和肿瘤坏死因子-α（TNF-α）。
XBJ作为辅助治疗可改善手足口病的预后，且安全性良好，其治疗作用具有特定的分子靶点。
